

Technology Advisory Interests Register

Topic: Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Will Sullivan	TAC Committee Member	Financial	Through my salaried consultancy role, I have one project to declare for the last 12 months, relating to ID6474. This is ongoing work with Novartis' US team regarding asciminib to treat newly diagnosed chronic myelogenous leukemia. Asciminib is not a comparator treatment, I list this for completeness as Novartis is listed for three other technologies, none of which I have a conflict for.	19/08/2025 16/10/2025	It was agreed that Will's declaration would not prevent them from participating in discussions on this appraisal
Bernard Khoo	TAC Committee Member	Non-financial professional	I am a physician who treats patients with neuroendocrine tumours.	10/09/2025 21/10/2025	It was agreed that Bernard's declaration would not prevent them from participating in discussions on this appraisal
Dr Charlotte Fribbens	Expert	Direct – financial	Advisory board member Novartis (NETTER-2)	08/04/2025	It was agreed that Dr Fribbens's declaration

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Debashis Sarker	Expert		Sponsorship to attend meeting – ENETS (Novartis), ESMO (Takeda)	14/04/2025 12/11/2025	It was agreed that Dr Sarker's declaration would not prevent them from providing expert advice to the committee
		Direct – non-financial	Chair of Royal Marsden drugs and therapeutics committee		
		Direct – financial	Travel and conference expenses (registration, flights, hotel) from Ipsen: ENETS meeting March 2024 and 2025- not related to cabozantinib Speaker fees from Ipsen May 2024 and April 2025 – not related to cabozantinib		
		Direct – non-financial	Neuroendocrine Cancer UK- Medical Advisory Board member		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			MHRA Member, MHRA Commission on Human Medicines, Oncology Haematology Expert Advisory Group		
		Indirect	<p>Advisory Boards/Consultancy fees received 2020-2025: Eisai, Ipsen, Astra Zeneca, AAA, Sirtex, Roche, Incyte, Abbvie, Boehringer, Servier, Bayer</p> <p>Speaker fees for educational meetings 2020-2025: Ipsen, Eisai, Bayer, Servier, AstraZeneca, Incyte, MSD, Bayer</p> <p>Travel and conference fees 2020-2025: Ipsen, Servier, Boehringer, Bayer, Servier</p>		
Nikie Jervis	Expert	Financial	Neuroendocrine Cancer UK has received unrestricted grants from Ipsen for educational purposes	10/09/2025	It was agreed that Nikie's declaration would not prevent them from providing expert advice to the committee